Recent Patents on Biotechnology - Volume 2, Issue 3, 2008

Fundamental research into how microbes generate electricity within microbial fuel cells (MFCs) has far outweighed the practical application and large scale development of microbial energy harvesting devices. MFCs are considered alternatives to standard commercial polymer electrolyte membrane (PEM) fuel cell technology because the fuel supply does not need to be purified, ambient operating temperatures are maintained with biologically compatible materials, and the biological catalyst is self-regenerating. The generation of electricity during wastewater treatment using MFCs may profoundly affect the approach to anaerobic treatment technologies used in wastewater treatment as a result of developing this energy harvesting technology. However, the materials and engineering designs for MFCs were identical to commercial fuel cells until 2003. Compared to commercial fuel cells, MFCs will remain underdeveloped as long as low power densities are generated from the best systems. The variety of designs for MFCs has expanded rapidly in the last five years in the literature, but the patent protection has lagged behind. This review will cover recent and important patents relating to MFC designs and progress.

The demand for plasmid DNA has increased vastly in response to rapid advances in its use in gene therapy and vaccines. These therapies are based on the same principle, i.e. the introduction of nucleic acids in human/non-human cells receptor to restore, cancel, enhance or introduce a biochemical function. Naked plasmid DNA as a vector has attracted a lot of interest since it offers several advantages over a viral vector, especially weak immunogenicity, better safety and easy to manufacture, but low transfection efficacy. Non-viral gene therapy may require considerable amounts (milligram scale) of pharmaceutical-grade pDNA per patient since the efficacy and duration of gene expression is presently relatively low. Reliance on fermentation, which generates large lysate volumes, for producing the needed quantities of pDNA is becoming more widespread. Through optimization of the biological system, growth environment and the growth mode, improvements can be achieved in biomass productivity, plasmid yield, plasmid quality and production costs. The information on large-scale plasmid production is scarce and usually not available to the scientific community. This review summarizes recent patents and patent applications relating to plasmid upstream processing manufacturing, ranging from plasmid design to growth strategies to produce plasmid-bearing E. coli.

The rapidly expanding market for bioethanol and biodiesel is remarkably altering the cost and availability of glycerol. In general, approximately 10 pounds of crude glycerol are formed for every 100 pounds of biodiesel produced. Bioethanol process also generates glycerol up to 10% (w/w) of the total sugar consumed as a byproduct. Crude glycerol has thus been widely recognized as an attractive sustainable resource for chemical industries. Glycerol-based biorefinery is the microbial fermentation processes using inexpensive and readily available glycerol as the raw material to produce fuels and chemicals. A major challenge in fermentation of the low-grade crude glycerol is to obtain microbial strains tolerant to undesirable inhibitory components such as salts and organic solvents that present in crude glycerol. There have been several attempts to explore anaerobic microbial assimilation of glycerol using reconstructed microbial systems via microbial screening and metabolic pathway engineering. As a result, fuels as well as some high-value products were found to be produced by microbial fermentation of glycerol. This review describes biological processes using glycerol that produce fuels and chemicals including 1,3-propanediol, ethanol and organic acids.

ErbBs signalling is always associated with the development of the majority of solid cancers via both the MAPK pathway leading to cell cycle progression and the PI3K pathway causing cell survival. As a consequence, many ErbB antagonists have been developed and patented for cancer treatment purposes. These antagonists belong to two drug classes: monoclonal antibodies (mAbs) and small molecules competing with ATP and inhibiting the tyrosine kinase domain (TKIs). Three patented mAbs are currently approved in clinical cancer treatment: Trastuzumab (Herceptin) directed against HER2 and used to treat breast cancer, Cetuximab and Panitumumab which are anti-EGFR antibodies approved for colorectal cancer treatment. Unfortunately, these mAbs are facing cancer resistance mediated by paracrine activation of other ErbB members or compensatory ErbB signalling factors. In parallel, three TKIs have been approved to treat cancer: Gefitinib (Iressa®), Erlotinib (Tarceva®) inhibiting specifically EGFR and approved to treat non small cell lung cancer and Lapatinib (Tykerb®) which has the dual specificity EGFR/HER2 and recently approved to treat metastatic breast cancer. These TKIs are also facing resistance mutations within the TK domain which increase its affinity to ATP. Resistance problems are leading to the adoption of a new strategy based on the combination of different therapies and this is likely to be the most promising future of cancer treatments.

The effects of hydrogen peroxide on enterokinase catalysis were studied using several fusion proteins recombinantly produced from E. coli. It was demonstrated that hydrogen peroxide enhanced the rate of enterokinase cleavage reaction, leading to a faster release of the target peptide as discussed in patent WO07149053 [1] . Among the conditions tested, we observed that hydrogen peroxide could exert its effect on the cleavage of fusion proteins over a wide range of pH and temperature. This finding might provide a simple solution for the accelerated enterokinase cleavage of thermolabile fusion proteins at low temperature.

The introduction of economic production processes for 1,3-propanediol is a success story for the creation of a new market for a (bulk) chemical. The compound and its favorable properties have long been known; also the fermentation of glycerol to 1,3-propanediol had been described more than 120 years ago. Nevertheless, the product remained a specialty chemical until recently, when two new processes were introduced, providing 1,3-propanediol at a competitive price. Remarkably, one of the processes is in the field of white biotechnology and based on microbial fermentation, converting a renewable carbon source into a bulk chemical. This review covers the most important patents that led to the commercialization of bio-based 1,3-propanediol. Furthermore, some of the recent developments towards a sustainable industry are addressed. Similar questions arise for a variety of products if they are to be produced bio-based in large scale. However, special emphasis is given to 1,3- propanediol production.

Agrobacterium-mediated transient expression is a recently developed approach to quick and inexpensive largescale production of recombinant proteins in plant systems. In the course of this process, foreign gene expression occurs during several days after agroinfiltration without integration of recombinant DNA into plant genome and the level of target protein synthesis may be considerably higher than in stably transformed plants. This mini-review describes biological peculiarities of transient expression process, method development and optimization, and the range of application for biotechnological production of variable proteins. Patenting the transient expression protocols that mostly occurred during new millennium indicates the growing interest to this method as a perspective alternative to “classical” pro- and eukaryotic systems for recombinant protein production.

Transcription factors are clue elements in the regulation of signal transduction pathways in living organisms. These proteins are able to recognize and bind specific sequences in the promoter regions of their targets and subsequently activate or repress entire metabolic or developmental processes. About 1500 TFs were informatically identified in plants, analysis mainly based in the presence of DNA-binding domains in the translated sequences. However, only a few of these 1500 were functionally characterized and clearly classified as TFs. Among these, several seem to be powerful biotechnological tools in order to improve agronomic crops via the obtaining of transgenic plants or as molecular markers. Such TFs have become the objects of patents presentations in the whole world. The assigned uses present a variety of purposes including the improvement in yield, abiotic and biotic stresses tolerances as well as a combination of them. Some examples are commented in the present overview. Most of these TFs confer to transgenic plants complex phenotypes due to a combination of different regulated pathways. In this sense, the use of inducible promoters instead of constitutive ones seems in some cases to be useful to limit the changed phenotype to the desired one, avoiding lateral effects. None of these TFs was converted up to now in a market product since time-consuming experiments and regulation permits are required to arrive to such point. Moreover, a considerable money investment must be done, not justified in all cases. However, it is likely that these molecules will become in the near future the first choice for breeders since it was demonstrated that TFs are very efficient conferring desired traits to transgenic plants. Additionally, for the public perception the over or ectopic expression of a plant gene should be more accepted than the use of molecules from other species.

PI3K-Akt pathway is an important mechanism through which viral infection influences various cell functions. Activating PI3K-Akt signaling is a strategy employed by viruses to slow down apoptosis and prolong viral replication in both acute and persistent infection. It is also probable that prevention of cell death facilitates virus-induced carcinogenesis. Accumulating evidence suggests that the activity of PI3K or Akt is critical for survival of a few viruses. Adenovirus relies on PI3K-mediated organization of actin filament for active internalization. Non-segmented negativesense RNA viruses require Akt to enhance synthesis of viral RNAs. On the other hand, PI3K-Akt signaling is associated with up-regulating interferon response. Higher PI3K-Akt activity might impede viral propagation due to activation of cellular defenses. Influenza A virus is an interesting case which requires active PI3K for penetration despite the negative effects of inducing immune response. Unlike most viruses, it was reported that VP1 protein of foot-and-mouth disease virus inhibits Akt to promote cell death. These reports confirm the multiple roles of PI3K-Akt pathway in viral infection. Here, more new information on the interaction between PI3K-Akt signaling and viral infection is discussed.

Full text available